| The effect of incentive-based formularies on prescription-drug utilization and spending HA Huskamp, PA Deverka, AM Epstein, RS Epstein, KA McGuigan, ... New England Journal of Medicine 349 (23), 2224-2232, 2003 | 441 | 2003 |
| Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement PA Deverka, DC Lavallee, PJ Desai, LC Esmail, SD Ramsey, ... Journal of comparative effectiveness research 1 (2), 181-194, 2012 | 348 | 2012 |
| Genetic test availability and spending: where are we now? Where are we going? KA Phillips, PA Deverka, GW Hooker, MP Douglas Health affairs 37 (5), 710-716, 2018 | 233 | 2018 |
| Validation of a new quality of life questionnaire for benign prostatic hyperplasia RS EPSTEIN, PA Deverka, CG Chute, JE Oesterling, MM Lieber, ... Journal of clinical epidemiology 45 (12), 1431-1445, 1992 | 208 | 1992 |
| Research directions in the clinical implementation of pharmacogenomics: an overview of US programs and projects S Volpi, CJ Bult, RL Chisholm, PA Deverka, GS Ginsburg, HJ Jacob, ... Clinical Pharmacology & Therapeutics 103 (5), 778-786, 2018 | 114 | 2018 |
| Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women … SD Ramsey, WE Barlow, AM Gonzalez-Angulo, S Tunis, L Baker, ... Contemporary clinical trials 34 (1), 1-9, 2013 | 110 | 2013 |
| Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer DR Parkinson, RT McCormack, SM Keating, SI Gutman, SR Hamilton, ... Clinical Cancer Research 20 (6), 1428-1444, 2014 | 108 | 2014 |
| Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children HA Huskamp, PA Deverka, AM Epstein, RS Epstein, KA McGuigan, ... Archives of general psychiatry 62 (4), 435-441, 2005 | 82 | 2005 |
| Economic opportunities and challenges for pharmacogenomics PA Deverka, J Vernon, HL McLeod Annual review of pharmacology and toxicology 50, 423-437, 2010 | 77 | 2010 |
| Opportunities, resources, and techniques for implementing genomics in clinical care TA Manolio, R Rowley, MS Williams, D Roden, GS Ginsburg, C Bult, ... The Lancet 394 (10197), 511-520, 2019 | 74 | 2019 |
| Clinical integration of next generation sequencing: coverage and reimbursement challenges PA Deverka, JC Dreyfus Journal of Law, Medicine & Ethics 42 (S1), 22-41, 2014 | 73 | 2014 |
| The costs of prostatectomy for benign prostatic hyperplasia KA Weis, RS Epstein, DM Huse, PA Deverka, G Oster The Prostate 22 (4), 325-334, 1993 | 71 | 1993 |
| Urinary symptom and quality of lifequestions indicative of obstructive benign prostatic hyperplasia: Results of a pilot study RS Epstein, PA Deverka, CG Chute, MM Lieber, JE Oesterling, L Panser, ... Urology 38 (1), 20-26, 1991 | 69 | 1991 |
| Pharmacogenomics, evidence, and the role of payers PA Deverka Public Health Genomics 12 (3), 149-157, 2009 | 68 | 2009 |
| Methodological issues in assessing the economic value of next-generation sequencing tests: many challenges and not enough solutions KA Phillips, PA Deverka, DA Marshall, S Wordsworth, DA Regier, ... Value in Health 21 (9), 1033-1042, 2018 | 67 | 2018 |
| Beyond Survey Data: A Claims-Based Analysis Of Drug Use And Spending By The Elderly: Spending for prescription drugs is not distributed evenly across the elderly population … EP Steinberg, B Gutierrez, A Momani, JA Boscarino, P Neuman, ... Health Affairs 19 (2), 198-211, 2000 | 67 | 2000 |
| Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research KA Phillips, PA Deverka, HC Sox, MJ Khoury, LG Sandy, GS Ginsburg, ... Genetics in Medicine 19 (10), 1-11, 2017 | 65 | 2017 |
| Integrating molecular medicine into the US health‐care system: opportunities, barriers, and policy challenges PA Deverka, T Doksum, RJ Carlson Clinical Pharmacology & Therapeutics 82 (4), 427-434, 2007 | 61 | 2007 |
| Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia SA Kaplan, ET Goluboff, CA Olsson, PA Deverka, JJ Chmiel Urology 45 (3), 398-405, 1995 | 56 | 1995 |
| Payer coverage policies for multigene tests KA Phillips, PA Deverka, JR Trosman, MP Douglas, JD Chambers, ... Nature biotechnology 35 (7), 614-617, 2017 | 55 | 2017 |
